Cite
Ducret A, Ackaert C, Bessa J, et al. Assay format diversity in pre-clinical immunogenicity risk assessment: Toward a possible harmonization of antigenicity assays. MAbs. 2022;14(1):1993522doi: 10.1080/19420862.2021.1993522.
Ducret, A., Ackaert, C., Bessa, J., Bunce, C., Hickling, T., Jawa, V., Kroenke, M. A., Lamberth, K., Manin, A., Penny, H. L., Smith, N., Terszowski, G., Tourdot, S., & Spindeldreher, S. (2022). Assay format diversity in pre-clinical immunogenicity risk assessment: Toward a possible harmonization of antigenicity assays. mAbs, 14(1), 1993522. https://doi.org/10.1080/19420862.2021.1993522
Ducret, Axel, et al. "Assay format diversity in pre-clinical immunogenicity risk assessment: Toward a possible harmonization of antigenicity assays." mAbs vol. 14,1 (2022): 1993522. doi: https://doi.org/10.1080/19420862.2021.1993522
Ducret A, Ackaert C, Bessa J, Bunce C, Hickling T, Jawa V, Kroenke MA, Lamberth K, Manin A, Penny HL, Smith N, Terszowski G, Tourdot S, Spindeldreher S. Assay format diversity in pre-clinical immunogenicity risk assessment: Toward a possible harmonization of antigenicity assays. MAbs. 2022 Jan-Dec;14(1):1993522. doi: 10.1080/19420862.2021.1993522. PMID: 34923896; PMCID: PMC8726688.
Copy
Download .nbib